Bi-Functional Anti-Tau Polypeptides and Use Thereof

ABSTRACT

Disclosed herein are multifunctional polypeptides comprising a first domain comprising an anti-tau antigen binding domain and a second domain comprising a proteasome-targeting PEST motif, and methods for using these polypeptides in treatment of tauopathies.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 16/331,063, filed Mar. 6, 2019 which is a U.S. National Phase application under 35 U.S.C. § 371 of International Patent Application No. PCT/US2017/050764 filed Sep. 8, 2017, which PCT/US2017/050764 claims the benefit of priority of U.S. Provisional Application No. 62/385,019, filed Sep. 8, 2016, the contents of which are incorporated by reference herein in their entirety.

SEQUENCE LISTING

This document includes a sequence listing submitted to the United States Patent and Trademark Office via the electronic filing system as an ASCII text file. The sequence listing, which is incorporated-by-reference herein, is titled “Sequence_listing,” was created on Jun. 1, 2021, and has a size of 123 kilobytes.

TECHNICAL FIELD

This invention relates to multifunctional polypeptides comprising an anti-tau antibody or functional fragment thereof, and methods for using these polypeptides in treatment of tauopathies.

BACKGROUND

Tau is a microtubule-associated phosophoprotein expressed in the central and peripheral nervous system. Tau plays a role in many biological processes such as microtubule stabilization, neurite outgrowth, neuronal migration, signal transduction, and organelle transport. Under normal conditions, tau expression is abundant within the axons of neurons. The misfolding and aggregation of tau within neurons are defining pathological hallmarks in a variety of neurodegenerative diseases collectively known as tauopathies. Tauopathies include Alzheimer's disease (AD), Fronto-temporal Dementia with Parkinsonism on chromosome-17 (FTDP-17), Pick's disease, Corticobasal Degeneration (CBD), Progressive Supranuclear Palsy (PSP), Dementia pugilistica (chronic traumatic encephalopathy), Lytico-Bodig disease, ganglioglioma and gangliocytoma, Meningioangiomatosis, Subacute sclerosing panencephalitis, lead encephalopathy, Tuberous sclerosis, Hallervorden-Spatz disease and others. The incidence of tauopathies represent an urgent and unmet medical need.

In tauopathies, tau protein loses its ability to bind to microtubules, and as a result tau is mislocalized to the dendritic compartment of the neuron. During this process, tau is hyperphosphorylated and misfolds into insoluble aggregates of straight filaments and paired helical filaments (PHF) which comprise neurofibrillary tangles and threads (NFTs). Tau hyperphosphorylation is presumed to occur prior to NFT formation. Furthermore, abnormal Tau can recruit the properly folded isoform into misfolded complexes and, the abnormal form can be secreted from one cell and be taken up by other cells, which can trigger a cascade of misfolded Tau complexes.

Immunotherapy for the reduction in the intracellular levels of tau available for misfolding and/or aggregation represents a potential therapeutic approach for the treatment of tauopathies. Full-length antibodies that bind tau, however, have limited penetration into brain cells where tau protein aggregates reside.

SUMMARY

This disclosure features bi-functional polypeptides that specifically bind to tau and their use to treat and prevent tauopathies, such as Alzheimer's disease. The bi-functional polypeptides disclosed herein comprise a first domain comprising an antigen binding domain of an antibody or antigen binding functional fragment thereof which binds to an epitope of Tau. The bi-functional polypeptides disclosed herein further comprise a second domain comprising a proteasomal targeting PEST degron to enhance the degradation of tau following association with the bi-functional polypeptide. In one aspect, the disclosure provides an isolated bi-functional bi-functional polypeptide that specifically binds to tau, wherein the polypeptide comprises a first domain comprising an antigen binding domain of an antibody or antigen binding functional fragment thereof which binds to an epitope of Tau, and a second domain comprising a proteasome-targeting PEST motif. In some aspects, the bi-functional polypeptide is a single chain polypeptide.

In certain embodiments, the antigen binding domain of an antibody or functional antigen binding fragment thereof is selected from the group consisting of a Fab, a Fab′, a F(ab′)2, a Fv, a diabody, a scFv, and a sc(Fv)2.

In certain embodiments, the first domain is an intrabody.

In certain embodiments, the first domain is a single chain fragment (scFv) which binds to an epitope of tau. For example, in some embodiments, first domain is a scFv which comprises a tau specific V_(L) domain (V_(L)Tau) and a Tau specific V_(H) domain (V_(H)Tau).

In one aspect, a bi-functional polypeptide comprises a first domain that comprises a single chain fragment (scFv) which binds to an epitope of tau and a second domain comprising a proteasome-targeting PEST motif. In some embodiments, the domains are arranged in the order of V_(L)Tau-V_(H)Tau-PEST motif. In some embodiments, the domains are arranged in the order of V_(H)Tau-V_(L)Tau-PEST motif.

The PEST motif may be derived from either mouse or human short-lived proteins, such as ornithine decarboxylase (ODC).

In certain embodiments, this disclosure features a bi-functional polypeptide comprising a first domain, wherein the first domain comprises an antigen binding domain of an antibody or functional fragment thereof.

In some embodiments, the bi-functional polypeptide comprises a first domain is a single chain fragment (scFv) which binds to an epitope of tau, the scFv comprising a Tau specific V_(L) domain (V_(L) Tau) and a Tau specific V_(H) domain (V_(H) Tau).

In some embodiments, the scFv comprises a Tau specific V_(L) domain (V_(L) Tau) or antigen binding fragment thereof having an amino acid sequence that is:

BEGIN HERE at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 18;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 19;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 20;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 21;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 22;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical an amino acid sequence as set forth in SEQ ID NO: 23;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 24;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 25;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 26;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 27;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 28;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 29;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 30;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 31;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 32;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 33; or

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 34.

In some embodiments, the scFv comprises a Tau specific V_(H) domain (V_(H) Tau) or antigen binding fragment thereof having an amino acid sequence that is:

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 1;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 2;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 3;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 4;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 5;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 6;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 7;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 8;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 9;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 10;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 11;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 12;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 13;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 14;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 15;

at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 16; or at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 17.

In certain embodiments, the Tau specific VL domain (V_(L) Tau) and a Tau specific V_(H) domain (V_(H) Tau) are connected via a linker. For example, the Tau specific VL domain (V_(L) Tau) and a Tau specific VH domain (V_(H) Tau) are connected via a linker that has an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid set forth in SEQ ID NO: 35 (GGGGSGGGGSGGGGS) or SEQ ID NO: 37 (YPYDVPDYA).

In certain embodiments, this disclosure features a bi-functional polypeptide comprising a second domain, wherein the second domain comprises a proteasome-targeting PEST motif that has an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid set forth in SEQ ID NO: 36 (SHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARIN).

In certain embodiments, this disclosure features a bi-functional polypeptide comprising a second domain, wherein the second domain comprises a proteasome-targeting PEST motif corresponding to the human ODC₄₂₂₋₄₆₁ PEST having an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid set forth in SEQ ID NO: 38 (NPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV).

In certain embodiments, this disclosure features a bi-functional polypeptide comprising a second domain, wherein the second domain comprises a proteasome-targeting PEST motif corresponding to the human ODC₄₂₂₋₄₆₁ PEST having an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid set forth in SEQ ID NO: 39 (SHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV).

In certain embodiments, the first and second domain are connected by a polypeptide linker. One such polypeptide linker comprises an amino acid sequence having at least 80% identity to SEQ ID NO: 3.

In certain embodiments, the first domain is a single-chain fragment (scFv) of an anti-tau antibody.

In certain embodiments, the first domain is a single domain antibody (dAb; either V_(H) or V_(L)) of the antibody which binds to an epitope of Tau.

In some embodiments, the first domain binds to an epitope comprising amino acids 312-322 of SEQ ID NO: 7. In some embodiment, the first domain binds to an epitope comprising amino acids 150 to 190 of SEQ ID NO: 7.

In another aspect, the disclosure provides a polynucleotide encoding single-chain bi-functional polypeptide which comprises a first domain comprising an antigen binding domain of an antibody or functional fragment thereof which binds to an epitope of Tau; and a second domain comprising a proteasome-targeting PEST motif The polynucleotides can be incorporated into a vector. Also contemplated are isolated host cells transfected with a polynucleotide or vector described herein.

In another aspect, the disclosure provides an isolated nucleic acid comprising a nucleotide sequence that encodes an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence set forth in SEQ ID Nos: 1-34. The proteins encoded by these nucleic acids specifically bind to tau. This disclosure also includes proteins encoded by any of the above nucleic acids. In addition, this disclosure includes recombinant vectors comprising any of the above nucleic acids. Furthermore, this application provides host cells comprising recombinant vectors comprising any of the above nucleic acids.

In yet another aspect, this disclosure features a method of preparing a bi-functional polypeptide of the present disclosure, which method comprises culturing a host cell comprising recombinant vectors comprising the nucleic acid sequence encoding single-chain bi-functional polypeptide which comprises a first domain comprising an antigen binding domain of an antibody or functional fragment thereof which binds to an epitope of Tau; and a second domain comprising a proteasome-targeting PEST motif under conditions appropriate for expression of a polypeptide, wherein the polypeptide and a bi-functional polypeptide are both expressed. In certain embodiments, the method further involves isolating the bi-functional polypeptide. In some embodiments, the host cell is a CHO, 293E, or COS cell.

In certain embodiments, the antibody is monoclonal antibody, a synthetic antibody, a human or a humanized antibody.

In some embodiments, the bi-functional polypeptide is used to treat or prevent a tauopathy in a patient in need thereof, the use comprising administering to the patient the bi-functional polypeptide.

In one aspect, the disclosure provides methods of treating and preventing a tauopathy of a patient in need thereof.

In another aspect, the disclosure provides methods for the preparation of a single-chain bi-functional polypeptide, which methods comprise cultivating a host cell transfected with a polynucleotide which upon expression encodes a single-chain bi-functional polypeptide as described herein; and isolating the polypeptide from the cell.

In yet a further aspect, the disclosure provides compositions comprising a single-chain bi-functional polypeptide, the bi-functional polypeptide comprising a first domain comprising an antigen binding domain of an antibody or functional fragment thereof which binds to an epitope of Tau; and a second domain comprising a proteasome-targeting PEST motif. In some embodiments, the composition is a pharmaceutical composition further comprising a pharmaceutically acceptable carrier.

In certain embodiments, this disclosure features a bi-functional polypeptide that binds to an epitope of Tau, the bi-functional polypeptide comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to any one of SEQ ID NOs: 40 to 56.

In certain embodiments, this disclosure features a bi-functional polypeptide that binds to an epitope of Tau, the bi-functional polypeptide comprising an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 97%, or 100% identical to any one of SEQ ID NOs: 57 to 73.

In another aspect, the disclosure provides an isolated nucleic acid comprising a nucleotide sequence that encodes an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence set forth in SEQ ID NOs: 40 to 73.

In another aspect, the disclosure provides methods for the treatment of a tauopathy in a patient in need of such treatment, which comprises administering to the patient in need of such treatment an effective amount for treating the tauopathy of a single-chain bi-functional polypeptide, which comprises a first domain comprising an antigen binding domain of an antibody or fragment thereof which binds to an epitope of Tau; and a second domain comprising a proteasome-targeting PEST motif. Tauopathies that may be treated according to the method include, but are not limited to, Alzheimer disease (AD), Down syndrome, Guam parkinsonism dementia complex, Dementia pugilistica, Pick disease, Dementia with argyrophilic grains, Fronto-temporal dementia, Cortico-basal degeneration, Pallido-ponto-nigral degeneration, Progressive supranuclear palsy, and Gerstmann-Sträussler-Scheinker disease. The administering step can include administering to the patient a polynucleotide which upon expression encodes a single-chain bi-functional polypeptide which comprises a first domain comprising an antigen binding domain of an antibody or fragment thereof which binds to an epitope of Tau; and a second domain comprising a proteasome-targeting PEST motif. In some embodiments, treatment inhibits or slows down formation of tau aggregates in (the brain of, a cell of) the patient. In some embodiments, treatment inhibits or slows down formation of neurofibrillary tangles in (the brain of) the patient.

The present disclosure provides antigen-binding domains of an antibody or functional fragments thereof and similar antigen-binding molecules which are capable of specifically recognizing tau. By “specifically recognizing tau”, “antibody specific to/for tau” and “anti-tau antibody” is meant specifically, generally, and collectively, antibodies to the native form of tau, phosphorylated forms of tau, or aggregated or pathologically modified tau isoforms

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Methods and materials are described herein for use in the present invention; other, suitable methods and materials known in the art can also be used. The materials, methods, and examples are illustrative only and not intended to be limiting. All publications, patent applications, patents, sequences, database entries, and other references mentioned herein are incorporated by reference in their entirety. In case of conflict, the present specification, including definitions, will control.

Other features and advantages of the invention will be apparent from the following detailed description and figures, and from the claims.

DESCRIPTION OF DRAWINGS

FIG. 1 is an alignment of seventeen anti-Tau heavy chain variable region amino acid sequences. The CDRs (according to Kabat) are in bold

FIG. 2 is an alignment of seventeen anti-Tau light chain variable region amino acid sequences. The CDRs (according to Kabat) are in bold.

FIG. 3 depicts representative live cell images of tau-GFP expressing ST14A cells 48 hours post transfection control (CON+GFP-tau; empty pcDNA3.1 plasmid) or anti-Tau-PEST bi-functional polypeptides according to the present disclosure. Images were taken at 32× magnification for each sample and then zoomed in digitally to cell level (Scale bar 20 μm).

FIG. 4 depicts representative live cell images of tau-GFP expressing ST14A cells 48 hours post transfection control (CON+GFP-tau; empty pcDNA3.1 plasmid) or anti-Tau-PEST bi-functional polypeptides according to the present disclosure. Images were taken at 32× magnification for each sample (Scale bar 50 μm).

DETAILED DESCRIPTION

This disclosure features polypeptides, e.g., bi-functional polypeptides, comprising an antigen binding domain of an antibody or functional fragment thereof, which binds to an epitope of Tau, and a proteasome-targeting PEST motif. The bi-functional polypeptides are useful in the treatment and prevention of tauopathies.

The antigen binding domain of an antibody or functional fragment thereof can bind to phosphorylated tau, hyperphosphorylated tau and/or aggregated tau with high specificity and/or high affinity. The amino acid sequence of the human tau protein (Genbank® Accession No. NP_001116538) is shown below:

(SEQ ID NO: 7) MAEPRQEFEVMEDHAGTYGLGDRKDQGGYTMHQDQEGDTDAGLKESPLQT PTEDGSEEPGSETSDAKSTPTAEDVTAPLVDEGAPGKQAAAQPHTEIPEG TTAEEAGIGDTPSLEDEAAGHVTQEPESGKVVQEGFLREPGPPGLSHQLM SGMPGAPLLPEGPREATRQPSGTGPEDTEGGRHAPELLKHQLLGDLHQEG PPLKGAGGKERPGSKEEVDEDRDVDESSPQDSPPSKASPAQDGRPPQTAA REATSIPGFPAEGAIPLPVDFLSKVSTEIPASEPDGPSVGRAKGQDAPLE FTFHVEITPNVQKEQAHSEEHLGRAAFPGAPGEGPEARGPSLGEDTKEAD LPEPSEKQPAAAPRGKPVSRVPQLKARMVSKSKDGTGSDDKKAKTSTRSS AKTLKNRPCLSPKHPTPGSSDPLIQPSSPAVCPEPPSSPKYVSSVTSRTG SSGAKEMKLKGADGKTKIATPRGAAPPGQKGQANATRIPAKTPPAPKTPP SSATKQVQRRPPPAGPRSERGEPPKSGDRSGYSSPGSPGTPGSRSRTPSL PTPPTREPKKVAVVRTPPKSPSSAKSRLQTAPVPMPDLKNVKSKIGSTEN LKHQPGGGKVQIINKKLDLSNVQSKCGSKDNIKHVPGGGSVQIVYKPVDL SKVTSKCGSLGNIHHKPGGGQVEVKSEKLDFKDRVQSKIGSLDNITHVPG GGNKKIETHKLTFRENAKAKTDHGAEIVYKSPVVSGDTSPRHLSNVSSTG SIDMVDSPQLATLADEVSASLAKQGL

As used herein, the term “antibody” includes intact immunoglobulins derived from natural sources or from recombinant sources, as well as immunoreactive portions (i.e., ‘antigen binding domains’ or ‘antigen binding portions’) of intact immunoglobulins. The antibodies of the present invention may exist in a variety of forms including, for example, polyclonal antibodies, monoclonal antibodies, intracellular antibodies (“intrabodies”), antibody fragments (e.g., Fv, Fab, Fab′, and F(ab′)2), as well as single chain antibodies (scFv), single domain V_(H) or V_(L) antibodies, chimeric antibodies, human antibodies and humanized antibodies.

Antibody fragments (e.g., Fv, Fab, Fab′, and F(ab′)2), such as antibody fragments of an anti-tau-binding antibody, may be prepared by proteolytic digestion of intact an antibody (e.g., and anti-tau antibody). For example, antibody fragments can be obtained by treating a whole antibody with an enzyme such as papain, pepsin, or plasmin. Papain digestion of whole antibodies produces F(ab)2 or Fab fragments; pepsin digestion of whole antibodies yields F(ab′)2 or Fab′; and plasmin digestion of whole antibodies yields Facb fragments.

Alternatively, antibody fragments, such as antibody fragments of an anti-tau-binding antibody, can be produced recombinantly. For example, nucleic acids encoding the antibody fragments of interest can be constructed, introduced into an expression vector, and expressed in suitable host cells. See, e.g., Co, M. S. et al., J. Immunol., 152:2968-2976 (1994); Better, M. and Horwitz, A. H., Methods in Enzymology, 178:476-496 (1989); Pluckthun, A. and Skerra, A., Methods in Enzymology, 178:476-496 (1989); Lamoyi, E., Methods in Enzymology, 121:652-663 (1989); Rousseaux, J. et al., Methods in Enzymology, (1989) 121:663-669 (1989); and Bird, R. E. et al., TIBTECH, 9:132-137 (1991)). For example, antibody fragments can be expressed in and secreted from E. coli, thus allowing the facile production of large amounts of these fragments. According to another approach, antibody fragments can be isolated directly from recombinant host cell culture.

As used herein, the term “epitope” designates a specific amino acid sequence, modified amino acid sequence, or protein secondary or tertiary structure which is specifically recognized by an antibody. The terms “specifically recognizing,” “specifically recognizes,” and any grammatical variants mean that the antibody or antigen-binding molecule thereof is capable of specifically interacting with and/or binding to at least two, at least three, or at least four amino acids of an epitope, e.g., a Tau epitope. Such binding can be exemplified by the specificity of a “lock-and-key-principle.” Thus, specific motifs in the amino acid sequence of the antigen-binding domain the tau antibody or antigen-binding molecule thereof and the epitope bind to each other as a result of their primary, secondary or tertiary structure as well as the result of secondary modifications of the structure.

As used herein “intrabody” means an intracellular or antibody fragment that can induce a phenotypic knockout, work as a neutralizing agent by direct binding to the target antigen, alter protein folding, protein-protein, protein-DNA, protein-RNA interactions and protein modification intracellularly.

The antigen binding domain of an antibody or functional fragment thereof of the present disclosure include single chain (scFv), single-chain (Fv)2 (sc(Fv)2), single domain antibodies (dAb; V_(H); V_(L)), and diabodies. scFV and single domain antibodies retain the binding specificity of full-length antibodies, but they can be expressed as single genes. scFV and single domain V_(H) or V_(L) antibodies may be applied both extracellularly and intracellularly (intrabodies).

An scFv is a single-chain polypeptide antibody obtained by linking the V_(H) and V_(L) of an antibody with a linker (see e.g., Huston et al., Proc. Natl. Acad. Sci. U S. A., 85:5879-5883 (1988); and Pluckthun, “The Pharmacology of Monoclonal Antibodies” Vol. 113, Ed Resenburg and Moore, Springer Verlag, New York, pp. 269-315, (1994)). The order of V_(H)S and V_(L)S to be linked is not particularly limited, and they may be arranged in any order. Examples of arrangements include: [V_(H)]-linker-[V_(L)]; or [V_(L)]-linker-[V_(H)]. The heavy chain variable region (V_(H)) and light chain variable region (V_(L)) in an scFv may be derived from any anti-tau antibody or antigen-binding fragment thereof described herein.

An sc(Fv)2 contains two V_(H)s and two V_(L)s which are linked by a linker to form a single chain (Hudson, et al., J. Immunol. Methods, (1999) 231: 177-189 (1999)). An sc(Fv)2 can be prepared, for example, by connecting scFvs with a linker. sc(Fv)2s may include two V_(H)s and two V_(L)s arranged in the order of: V_(H), V_(L), V_(H), and V_(L) ([V_(H)]-linker-[V_(L)]-linker-[V_(H)]-linker-[V_(L)]), beginning from the N terminus of a single-chain polypeptide; however, the order of the two V_(H)s and two V_(L)s is not limited to the above arrangement, and they may be arranged in any order. Examples of arrangements are listed below:

[V_(L)]-linker-[V_(H)]-linker-[V_(H)]-linker-[V_(L)]

[V_(H)]-linker-[V_(L)]-linker-[V_(L)]-linker-[V_(H)]

[V_(H)]-linker-[V_(H)]-linker [V_(L)]-linker-[V_(L)]

[V_(L)]-linker-[V_(L)]-linker-[V_(H)]-linker-[V_(H)]

[V_(L)]-linker-[V_(H)]-linker-[V_(L)]-linker-[V_(H)]

Normally, three linkers are required when four antibody variable regions are linked; the linkers used may be identical or different. There is no particular limitation on the linkers that link the V_(H) and V_(L) regions of the scFVs or sc(FV)2s. In some embodiments, the linker is a peptide linker. Any arbitrary single-chain peptide comprising about three to 25 residues (e.g., 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18) can be used as a linker.

The amino acid sequence of the V_(H) or V_(L) in the antigen binding domain of an antibody or functional fragment thereof may include modifications such as substitutions, deletions, additions, and/or insertions. For example, modifications, such as substitutions, deletions, additions, and/or insertions, made within the amino acid sequence of the V_(H) or V_(L) may be in one or more of the CDRs. In certain embodiments, the modification involves one, two, or three amino acid substitutions in one or more CDRs and/or framework regions of the V_(H) and/or V_(L) domain of the anti-tau antigen binding domain of an antibody or functional fragment thereof. Such substitutions are made to improve the binding, functional activity and/or reduce immunogenicity of the anti-tau antigen binding domain of an antibody or functional fragment thereof. In certain embodiments, the substitutions are conservative amino acid substitutions. In some embodiments, one, two, or three amino acids of the CDRs of the anti-tau antigen binding domain of an antibody or functional fragment thereof may be deleted or added, so as long as there is tau binding and/or functional activity when V_(H) and V_(L) are associated.

The proteasome-targeting PEST motif is a peptide sequence containing regions enriched in prolyl (P), glutamyl (E), aspartyl (D), seryl (S) and threonyl (T) residues (PEST regions) and are targeted for accelerated proteasomal degradation. This sequence is associated with proteins that have a short intracellular half-life. Mouse Ornithine DeCarboxylase (MODC) is one of the shortest half-lived proteins in mammals. The constitutive degradation of MODC by the proteasome is controlled by PEST sequences in its carboxy terminus (amino acids 422-461).

Exemplary murine derived PEST motif sequences include, for example, an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 36 (SHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARIN) and SEQ ID NO: 39 (SHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV).

Exemplary human derived PEST motif sequences (hPEST) include, for example, an amino acid sequence at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid sequence as set forth in SEQ ID NO: 38 (NPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV).

A comparison of mouse PEST (mPEST; SEQ ID NO: 39) and human PEST (hPEST; SEQ ID NO: 38) sequences is provided in Table 1, demonstrating 82.5% sequence homology between mouse mPEST and human hPEST.

TABLE 1 Sequence mPEST SHGFPPEVEEQDDGTLPMSCAQESGMDRHPAA (ODC-_(PEST422-461)) CASARINV (SEQ ID NO: 39) hPEST NPDFPPEVEEQDASTLPVSCAWESGMKRHRAA (ODC-PEST422- CASASINV (SEQ ID NO: 38) 461)

The term “% identical” between two polypeptide (or polynucleotide) sequences refers to the number of identical matched positions shared by the sequences over a comparison window, taking into account additions or deletions (i.e., gaps) that must be introduced for optimal alignment of the two sequences. A matched position is any position where an identical nucleotide or amino acid is presented in both the target and reference sequence. Gaps presented in the target sequence are not counted since gaps are not nucleotides or amino acids. Likewise, gaps presented in the reference sequence are not counted since target sequence nucleotides or amino acids are counted, not nucleotides or amino acids from the reference sequence. The percentage of sequence identity is calculated by determining the number of positions at which the identical amino acid residue or nucleic acid base occurs in both sequences to yield the number of matched positions, dividing the number of matched positions by the total number of positions in the window of comparison and multiplying the result by 100 to yield the percentage of sequence identity. The comparison of sequences and determination of percent sequence identity between two sequences can be accomplished using readily available software both for online use and for download. Suitable software programs are available from various sources, and for alignment of both protein and nucleotide sequences. One suitable program to determine percent sequence identity is bl2seq, part of the BLAST suite of program available from the U.S. government's National Center for Biotechnology Information BLAST web site (blast.ncbi.nlm.nih.gov). Bl2seq performs a comparison between two sequences using either the BLASTN or BLASTP algorithm. BLASTN is used to compare nucleic acid sequences, while BLASTP is used to compare amino acid sequences. Other suitable programs are, e.g., Needle, Stretcher, Water, or Matcher, part of the EMBOSS suite of bioinformatics programs and also available from the European Bioinformatics Institute (EBI) at www.ebi.ac.uk/Tools/psa. In certain embodiments, the percentage identity “X” of a first amino acid sequence to a second sequence amino acid is calculated as 100×(Y/Z), where Y is the number of amino acid residues scored as identical matches in the alignment of the first and second sequences (as aligned by visual inspection or a particular sequence alignment program) and Z is the total number of residues in the second sequence. If the length of a first sequence is longer than the second sequence, the percent identity of the first sequence to the second sequence will be higher than the percent identity of the second sequence to the first sequence. One skilled in the art will appreciate that the generation of a sequence alignment for the calculation of a percent sequence identity is not limited to binary sequence-sequence comparisons exclusively driven by primary sequence data. Sequence alignments can be derived from multiple sequence alignments. One suitable program to generate multiple sequence alignments is ClustalW2, available from www.clustal.org (ClustalX is a version of the ClustalW2 program ported to the Windows environment). Another suitable program is MUSCLE, available from www.drive5.com/muscle. ClustalW2 and MUSCLE are alternatively available, e.g., from the EBI.

The terms “linked” or “fused” refers to linkage via a peptide bonds (e.g., genetic fusion), chemical conjugation, or other means known in the art. For example, one way in which molecules or moieties can be linked employs peptide linkers that link the molecules or moieties via peptide bonds.

The term “associated with” refers to a covalent or non-covalent bond formed between a first amino acid chain and a second amino acid chain. In one embodiment, the term “associated with” means a covalent, non-peptide bond or a non-covalent bond. In another embodiment, the term “associated with” refers to a covalent, non-peptide bond or a non-covalent bond that is not chemically crosslinked. In another embodiment, it means a covalent bond except a peptide bond. In some embodiments this association is indicated by a colon, i.e., (:).

Method of Producing Polypeptides

The bi-functional polypeptides (or antigen binding domain of an antibody or functional fragment thereof) of this disclosure may be produced in bacterial or eukaryotic cells. To produce the polypeptide of interest, a polynucleotide encoding the polypeptide is constructed, introduced into an expression vector, and then expressed in suitable host cells. Standard molecular biology techniques are used to prepare the recombinant expression vector, transfect the host cells, select for transformants, culture the host cells and recover the antibody.

If the polypeptide is to be expressed in bacterial cells (e.g., E. coli), the expression vector should have characteristics that permit amplification of the vector in the bacterial cells. Additionally, when E. coli such as JM109, DHSα, HB101, or XL1-Blue is used as a host, the vector must have a promoter, for example, a lacZ promoter (Ward et al., 341:544-546 (1989), araB promoter (Better et al., Science, 240:1041-1043 (1988)), or T7 promoter that can allow efficient expression in E. coli. Examples of such vectors include, for example, M13-series vectors, pUC-series vectors, pBR322, pBluescript, pCR-Script, pGEX-5X-1 (Pharmacia), “QIAexpress system” (QIAGEN), pEGFP, and pET (when this expression vector is used, the host is preferably BL21 expressing T7 RNA polymerase). The expression vector may contain a signal sequence for antibody secretion. For production into the periplasm of E. coli, the pelB signal sequence (Lei et al., J. Bacteriol., 169:4379 (1987)) may be used as the signal sequence for antibody secretion. For bacterial expression, calcium chloride methods or electroporation methods may be used to introduce the expression vector into the bacterial cell.

In one embodiment, the polypeptides are produced in mammalian cells. Exemplary mammalian host cells for expressing a polypeptide include Chinese Hamster Ovary (CHO cells) (including dhfr⁻ CHO cells, described in Urlaub and Chasin (1980) Proc. Natl. Acad. Sci. USA 77:4216-4220, used with a DHFR selectable marker, e.g., as described in Kaufman and Sharp (1982) Mol. Biol. 159:601-621), human embryonic kidney 293 cells (e.g., 293, 293E, 293T), COS cells, NIH3T3 cells, lymphocytic cell lines, e.g., NS0 myeloma cells and SP2 cells, and a cell from a transgenic animal, e.g., a transgenic mammal.

If the polypeptide is to be expressed in mammalian cells such as CHO, COS, 293, 293T, and NIH3T3 cells, the expression vector includes a promoter necessary for expression in these cells, for example, an SV40 promoter (Mulligan et al., Nature, 277:108 (1979)), MMLV-LTR promoter, EF1α promoter (Mizushima et al., Nucleic Acids Res., 18:5322 (1990)), or CMV promoter. In addition to the nucleic acid sequence encoding the immunoglobulin or domain thereof, the recombinant expression vectors may carry additional sequences, such as sequences that regulate replication of the vector in host cells (e.g., origins of replication) and selectable marker genes. The selectable marker gene facilitates selection of host cells into which the vector has been introduced (see e.g., U.S. Pat. Nos. 4,399,216, 4,634,665 and 5,179,017). For example, typically the selectable marker gene confers resistance to drugs, such as G418, hygromycin, or methotrexate, on a host cell into which the vector has been introduced. Examples of vectors with selectable markers include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13.

The polypeptides of the present disclosure can be isolated from inside or outside (such as medium) of the host cell and purified as substantially pure and homogenous antibodies. Methods for isolation and purification commonly used for polypeptides purification may be used for the isolation and purification of polypeptides, and are not limited to any particular method. Polypeptides may be isolated and purified by appropriately selecting and combining, for example, column chromatography, filtration, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, and recrystallization. Chromatography includes, for example, affinity chromatography, ion exchange chromatography, hydrophobic chromatography, gel filtration, reverse-phase chromatography, and adsorption chromatography (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak et al., Cold Spring Harbor Laboratory Press, 1996). Chromatography can be carried out using liquid phase chromatography such as HPLC and FPLC. Columns used for affinity chromatography include protein A column and protein G column. Examples of columns using protein A column include Hyper D, POROS, and Sepharose FF (GE Healthcare Biosciences). The present disclosure also includes polypeptides that are highly purified using these purification methods.

Characterization of the Antigen Binding Domain of an Antibody or Antigen Binding Functional Fragment Thereof

The tau-binding properties of the polypeptides described herein may be measured by any standard method, e.g., one or more of the following methods: OCTET®, Surface Plasmon Resonance (SPR), BIACORE™ analysis, Enzyme Linked Immunosorbent Assay (ELISA), EIA (enzyme immunoassay), RIA (radioimmunoassay), and Fluorescence Resonance Energy Transfer (FRET).

The binding interaction of a protein of interest (an anti-tau antibody binding domain or functional fragment thereof) and a target (e.g., Tau) can be analyzed using the OCTET® systems. In this method, one of several variations of instruments (e.g., OCTET® QKe and QK), made by the FortéBio company are used to determine protein interactions, binding specificity, and epitope mapping. The OCTET® systems provide an easy way to monitor real-time binding by measuring the changes in polarized light that travels down a custom tip and then back to a sensor.

The binding interaction of a protein of interest (an anti-tau antibody binding domain or functional fragment thereof) and a target (e.g., tau) can be analyzed using Surface Plasmon Resonance (SPR). SPR or Biomolecular Interaction Analysis (BIA) detects biospecific interactions in real time, without labeling any of the interactants. Changes in the mass at the binding surface (indicative of a binding event) of the BIA chip result in alterations of the refractive index of light near the surface (the optical phenomenon of surface plasmon resonance (SPR)). The changes in the refractivity generate a detectable signal, which is measured as an indication of real-time reactions between biological molecules. Methods for using SPR are described, for example, in U.S. Pat. No. 5,641,640; Raether (1988) Surface Plasmons Springer Verlag; Sjolander and Urbaniczky (1991) Anal. Chem. 63:2338-2345; Szabo et al. (1995) Curr. Opin. Struct. Biol. 5:699-705 and on-line resources provide by BIAcore International AB (Uppsala, Sweden). Information from SPR can be used to provide an accurate and quantitative measure of the equilibrium dissociation constant (K_(d)), and kinetic parameters, including K_(on) and K_(off), for the binding of a biomolecule to a target.

Epitopes can also be directly mapped by assessing the ability of different anti-tau antibody binding domains or functional fragment thereof to compete with each other for binding to human tau using BIACORE chromatographic techniques (Pharmacia BIAtechnology Handbook, “Epitope Mapping”, Section 6.3.2, (May 1994); see also Johne et al. (1993) J. Immunol. Methods, 160:191-198).

When employing an enzyme immunoassay, a sample containing an antibody, for example, a culture supernatant of antibody-producing cells or a purified antibody is added to an antigen-coated plate. A secondary antibody labeled with an enzyme such as alkaline phosphatase is added, the plate is incubated, and after washing, an enzyme substrate such as p-nitrophenylphosphate is added, and the absorbance is measured to evaluate the antigen binding activity.

Additional general guidance for evaluating antibodies, e.g., Western blots and immunoprecipitation assays, can be found in Antibodies: A Laboratory Manual, ed. by Harlow and Lane, Cold Spring Harbor press (1988)).

Methods of Treatment

The bi-functional polypeptides described herein can be used in the treatment, including prevention, of tauopathies, such as, but not limited to Alzheimer's disease (AD), Fronto-temporal Dementia with Parkinsonism on chromosome-17 (FTDP-17), Pick's disease, Corticobasal Degeneration (CBD), Progressive Supranuclear Palsy (PSP), Dementia pugilistica (chronic traumatic encephalopathy), Lytico-Bodig disease, Ganglioglioma and gangliocytoma, Meningioangiomatosis, Subacute sclerosing panencephalitis, Llead encephalopathy, Tuberous sclerosis and Hallervorden-Spatz disease. Such methods comprise administering to a subject in need thereof (e.g., a subject suffering from or at risk of having a tauopathy) a therapeutically effective amount of a bi-functional polypeptide, which comprises a first domain comprising an antigen binding domain of an antibody or fragment thereof which binds to an epitope of tau; and a second domain comprising a proteasome-targeting PEST motif.

The term “subject” refers to an animal or human, or to one or more cells derived from an animal or human. Preferably, the subject is a human. Subjects can also include non-human primates.

Pharmaceutical Compositions

A bi-functional polypeptide as described herein can be formulated as a pharmaceutical composition for administration to a subject, e.g., to treat a disorder described herein. Typically, a pharmaceutical composition includes a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The composition can include a pharmaceutically acceptable salt, e.g., an acid addition salt or a base addition salt (see e.g., Berge, S. M., et al. (1977) J. Pharm. Sci. 66:1-19).

Pharmaceutical Formulation is a Well-Established.

Pharmaceutical formulation is a well-established art, and is further described, e.g., in Gennaro (ed.), Remington: The Science and Practice of Pharmacy, 20^(th) ed., Lippincott, Williams & Wilkins (2000) (ISBN: 0683306472); Ansel et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, 7^(th) Ed., Lippincott Williams & Wilkins Publishers (1999) (ISBN: 0683305727); and Kibbe (ed.), Handbook of Pharmaceutical Excipients American Pharmaceutical Association, 3^(rd) ed. (2000) (ISBN: 091733096X).

The pharmaceutical compositions may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (e.g., injectable and infusible solutions), dispersions or suspensions, tablets, pills, powders, liposomes and suppositories. The preferred form can depend on the intended mode of administration and therapeutic application. Typically compositions for the agents described herein are in the form of injectable or infusible solutions.

In one embodiment, a bi-functional polypeptide described herein is formulated with excipient materials, such as sodium citrate, sodium dibasic phosphate heptahydrate, sodium monobasic phosphate, Tween-80, and a stabilizer. It can be provided, for example, in a buffered solution at a suitable concentration and can be stored at 2-8° C. In some other embodiments, the pH of the composition is between about 5.5 and 7.5 (e.g., 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7.0, 7.1, 7.2, 7.3, 7.4, 7.5).

The pharmaceutical compositions can also include agents that reduce aggregation of the bi-functional polypeptide when formulated. Examples of aggregation reducing agents include one or more amino acids selected from the group consisting of methionine, arginine, lysine, aspartic acid, glycine, and glutamic acid. These amino acids may be added to the formulation to a concentration of about 0.5 mM to about 145 mM (e.g., 0.5 mM, 1 mM, 2 mM, 5 mM, 10 mM, 25 mM, 50 mM, 100 mM). The pharmaceutical compositions can also include a sugar (e.g., sucrose, trehalose, mannitol, sorbitol, or xylitol) and/or a tonicity modifier (e.g., sodium chloride, mannitol, or sorbitol) and/or a surfactant (e.g., polysorbate-20 or polysorbate-80).

Such compositions can be administered by a parenteral mode (e.g., intravenous, subcutaneous, intraperitoneal, or intramuscular injection). In one embodiment, the bi-functional polypeptide compositions are administered subcutaneously. In one embodiment, the bi-functional polypeptide compositions are administered intravenously. The phrases “parenteral administration” and “administered parenterally” as used herein mean modes of administration other than enteral and topical administration, usually by injection, and include, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraocular, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion.

The composition can be formulated as a solution, microemulsion, dispersion, liposome, or other ordered structure suitable for stable storage at high concentration. Sterile injectable solutions can be prepared by incorporating an agent described herein in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating an agent described herein into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze drying that yield a powder of an agent described herein plus any additional desired ingredient from a previously sterile-filtered solution thereof. The proper fluidity of a solution can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prolonged absorption of injectable compositions can be brought about by including in the composition an agent that delays absorption, for example, monostearate salts and gelatin.

In certain embodiments, the bi-functional polypeptide may be prepared with a carrier that will protect the compound against rapid release, such as a controlled release formulation, including implants, and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Many methods for the preparation of such formulations are patented or generally known. See, e.g., Sustained and Controlled Release Drug Delivery Systems, J. R. Robinson, ed., Marcel Dekker, Inc., New York (1978).

In one embodiment, the pharmaceutical formulation comprises a bi-functional polypeptide at a concentration of about 0.5 mg/mL to 500 mg/mL (e.g., 0.5 mg/mL, 1 mg/mL, 5 mg/mL, 10 mg/mL, 25 mg/mL, 30 mg/mL, 35 mg/mL, 40 mg/mL, 45 mg/mL, 50 mg/mL, 55 mg/mL, 60 mg/mL, 65 mg/mL, 70 mg/mL, 75 mg/mL, 80 mg/mL, 85 mg/mL, 90 mg/mL, 95 mg/mL, 100 mg/mL, 125 mg/mL, 150 mg/mL, 175 mg/mL, 200 mg/mL, 250 mg/mL, 300 mg/mL, 350 mg/mL, 400 mg/mL, 450 mg/mL, 500 mg/mL), formulated with a pharmaceutically acceptable carrier. In some embodiments, the bi-functional polypeptide is formulated in sterile distilled water or phosphate buffered saline. The pH of the pharmaceutical formulation may be between 5.5 and 7.5 (e.g., 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2 6.3, 6.4 6.5, 6.6 6.7, 6.8, 6.9 7.0, 7.1, 7.3, 7.4, 7.5).

Administration

The bi-functional polypeptide can be administered to a subject, e.g., a subject in need thereof, for example, a human or animal subject, by a variety of methods. For many applications, the route of administration is one of: intravenous injection or infusion (IV), subcutaneous injection (SC), intraperitoneally (IP), or intramuscular injection. Other modes of parenteral administration can also be used. Examples of such modes include: intraarterial, intrathecal, intracapsular, intraocular, intracardiac, intradermal, transtracheal, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, and epidural and intrasternal injection.

The route and/or mode of administration of the bi-functional polypeptide can also be tailored for the individual case, e.g., by monitoring the subject.

The bi-functional polypeptide can be administered as a fixed dose, or in a mg/kg dose. The dose can also be chosen to reduce or avoid production of antibodies against the bi-functional polypeptide. Dosage regimens are adjusted to provide the desired response, e.g., a therapeutic response or a combinatorial therapeutic effect. Generally, doses of the bi-functional polypeptide (and optionally a second agent) can be used in order to provide a subject with the agent in bioavailable quantities. For example, doses in the range of 0.1-100 mg/kg, 0.5-100 mg/kg, 1-100 mg/kg, 0.5-20 mg/kg, 0.1-10 mg/kg, or 1-10 mg/kg can be administered. Other doses can also be used. In certain embodiments, a subject in need of treatment with a bi-functional polypeptide is administered the bi-functional polypeptide at a dose of between about 1 mg/kg to about 30 mg/kg. In some embodiments, a subject in need of treatment with bi-functional polypeptide is administered the bi-functional polypeptide at a dose of 1 mg/kg, 2 mg/kg, 4 mg/kg, 5 mg/kg, 7 mg/kg 10 mg/kg, 12 mg/kg, 15 mg/kg, 20 mg/kg, 25 mg/kg, 28 mg/kg, 30 mg/kg, 35 mg/kg, 40 mg/kg, or 50 mg/kg. In a specific embodiment, the bi-functional polypeptide is administered subcutaneously at a dose of 1 mg/kg to 3 mg/kg. In another embodiment, the bi-functional polypeptide is administered intravenously at a dose of between 4 mg/kg and 30 mg/kg.

A composition may comprise about 1 mg/mL to 100 mg/ml or about 10 mg/mL to 100 mg/ml or about 50 to 250 mg/mL or about 100 to 150 mg/ml or about 100 to 250 mg/ml of the bi-functional polypeptide.

Dosage unit form or “fixed dose” as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of bi-functional polypeptide calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier and optionally in association with the other agent. Single or multiple dosages may be given. Alternatively, or in addition, the bi-functional polypeptide may be administered via continuous infusion.

A bi-functional polypeptide dose can be administered, e.g., at a periodic interval over a period of time (a course of treatment) sufficient to encompass at least 2 doses, 3 doses, 5 doses, 10 doses, or more, e.g., once or twice daily, or about one to four times per week, or preferably weekly, biweekly (every two weeks), every three weeks, monthly, e.g., for between about 1 to 12 weeks, preferably between 2 to 8 weeks, more preferably between about 3 to 7 weeks, and even more preferably for about 4, 5, or 6 weeks. Factors that may influence the dosage and timing required to effectively treat a subject, include, e.g., the stage or severity of the disease or disorder, formulation, route of delivery, previous treatments, the general health and/or age of the subject, and other diseases present. Moreover, treatment of a subject with a therapeutically effective amount of a compound can include a single treatment or, preferably, can include a series of treatments.

If a subject is at risk for developing a disorder described herein, the bi-functional polypeptide can be administered before the full onset of the disorder, e.g., as a preventative measure. The duration of such preventative treatment can be a single dosage of the bi-functional polypeptide or the treatment may continue (e.g., multiple dosages). For example, a subject at risk for the disorder or who has a predisposition for the disorder may be treated with the bi-functional polypeptide for days, weeks, months, or even years so as to prevent the disorder from occurring or fulminating.

A pharmaceutical composition may include a “therapeutically effective amount” of a bi-functional polypeptide as described herein. The term “therapeutically effective amount”, “pharmacologically effective dose”, “pharmacologically effective amount,” or simply “effective amount” may be used interchangeably and refers to that amount of an agent effective to produce the intended pharmacological, therapeutic or preventive result. The pharmacologically effective amount results in the amelioration of one or more symptoms of a disorder, or prevents the advancement of a disorder, or causes the regression of the disorder, or prevents the disorder. Such effective amounts can be determined based on the effect of the administered agent, or the combinatorial effect of agents if more than one agent is used. A therapeutically effective amount of an agent may also vary according to factors such as the disease stage, state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual, e.g., amelioration of at least one disorder parameter or amelioration of at least one symptom of the disorder. A therapeutically effective amount is also one in which any toxic or detrimental effects of the composition are outweighed by the therapeutically beneficial effects.

In certain embodiments, the bi-functional polypeptide is administered subcutaneously at a concentration of about 1 mg/mL to about 500 mg/mL (e.g., 1 mg/mL, 2 mg/mL, 3 mg/mL 4 mg/mL 5 mg/mL, 10 mg/mL, 15 mg/mL, 20 mg/mL, 25 mg/mL, 30 mg/mL, 35 mg/mL, 40 mg/mL, 45 mg/mL, 50 mg/mL, 55 mg/mL, 60 mg/mL, 65 mg/mL, 70 mg/mL, 75 mg/mL, 80 mg/mL, 85 mg/mL, 90 mg/mL, 95 mg/mL, 100 mg/mL, 125 mg/mL, 150 mg/mL, 175 mg/mL, 200 mg/mL, 225 mg/mL, 250 mg/mL, 275 mg/mL, 300 mg/mL, 325 mg/mL, 350 mg/mL, 400 mg/mL, 450 mg/mL). In one embodiment, the bi-functional polypeptide is administered subcutaneously at a concentration of 50 mg/mL. In another embodiment, the bi-functional polypeptide is administered intravenously at a concentration of about 1 mg/mL to about 500 mg/mL. In a particular embodiment, the bi-functional polypeptide is administered intravenously at a concentration of 50 mg/mL.

The bi-functional polypeptide can be administered to a patient in need thereof (e.g., a patient that has had or is at risk of having a tauopathy) alone or in combination with (i.e., by co-administration or sequential administration) other therapeutic proteins (e.g., antibodies, intrabodies, polypeptides) useful for treating a tauopathies may be desirable. In one embodiment, the additional therapeutic proteins are included in the pharmaceutical composition of the present invention. Examples of therapeutic proteins which can be used to treat a subject include, but are not limited to, therapeutic proteins targeting beta-amyloid, alpha-synuclein, TDP-43 and SOD-1.

The bi-functional polypeptide can be administered to a patient in need thereof (e.g., a patient that has or is at risk of having a tauopathy) in combination with (i.e., by co-administration or sequential administration) other neuroprotective agents useful for treating a tauopathy. In one embodiment, the additional agent is comprised of the pharmaceutical composition of the present invention. Examples of neuroprotective agents include, but are not limited to, an acetylcholinesterase inhibitor, a glutamatergic receptor antagonist, kinase inhibitors, HDAC inhibitors, anti-inflammatory agents, divalproex sodium, dopamine or a dopamine receptor agonist, or any combination thereof.

In some aspects, the bi-functional polypeptide described herein can be used in methods designed to express the bi-functional polypeptide intracellularly so as to bind intracellular tau. Such methods comprise delivering to a cell a bi-functional polypeptide which may be in any form used by one skilled in the art, for example, a protein, an RNA molecule which is translated, or a DNA vector which is transcribed and translated.

In instances where a polynucleotide molecule encoding a bi-functional polypeptide is used, the polynucleotide may be recombinantly engineered into a variety of host vector systems that can be introduced in vivo such that it is taken up by a cell and directs the transcription of the bi-functional polypeptide molecule. Such a vector can remain episomal or become chromosomally integrated, as long as it can be expressed to produce the desired polypeptide. Such vectors can be constructed by recombinant DNA technology methods that are well known and standard in the art. Vectors encoding the domain intrabody of interest can be plasmid, viral, or others known in the art, used for replication and expression in mammalian cells.

A wide variety of viral and non-viral vectors for delivery of a polynucleotide encoding a bi-functional polypeptide of the present disclosure are known in the art and may be employed in making the products and practicing the methods described herein. Vectors include, for example, eukaryotic expression vectors, including but not limited to viral expression vectors such as those derived from the class of retroviruses, adenoviruses or adeno-associated viruses.

Various vector systems are known to those skilled in the art and can be used to transfer the compositions of the invention into cells, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the composition, construction of a nucleic acid as part of a retroviral, adenoviral, adeno-associated viral or other vector, injection of DNA, electroporation, calcium phosphate mediated transfection, etc.

Devices and Kits for Therapy

Pharmaceutical compositions that include the bi-functional polypeptide described herein can be administered with a medical device. The device can be designed with features such as portability, room temperature storage, and ease of use so that it can be used in emergency situations, e.g., by an untrained subject or by emergency personnel in the field, removed from medical facilities and other medical equipment. The device can include, e.g., one or more housings for storing pharmaceutical preparations that include a bi-functional polypeptide, and can be configured to deliver one or more unit doses of the antibody. The device can be further configured to administer a second agent, e.g., a neuroprotective agent, either as a single pharmaceutical composition that also includes the bi-functional polypeptide or as two separate pharmaceutical compositions.

A bi-functional polypeptide can be provided in a kit. In one embodiment, the kit includes (a) a container that contains a composition that includes a bi-functional polypeptide as described herein, and optionally (b) informational material. The informational material can be descriptive, instructional, marketing or other material that relates to the methods described herein and/or the use of the agents for therapeutic benefit.

In an embodiment, the kit also includes a second agent for treating a disorder described herein. For example, the kit includes a first container that contains a composition that includes the bi-functional polypeptide, and a second container that includes the second agent.

The informational material of the kits is not limited in its form. In one embodiment, the informational material can include information about production of the compound, molecular weight of the compound, concentration, date of expiration, batch or production site information, and so forth. In one embodiment, the informational material relates to methods of administering the bi-functional polypeptide, e.g., in a suitable dose, dosage form, or mode of administration (e.g., a dose, dosage form, or mode of administration described herein), to treat a subject who has had or who is at risk for a tauopathy described herein. The information can be provided in a variety of formats, include printed text, computer readable material, video recording, or audio recording, or information that provides a link or address to substantive material, e.g., on the internet.

In addition to the bi-functional polypeptide, the composition in the kit can include other ingredients, such as a solvent or buffer, a stabilizer, or a preservative. The bi-functional polypeptide can be provided in any form, e.g., liquid, dried or lyophilized form, preferably substantially pure and/or sterile. When the agents are provided in a liquid solution, the liquid solution preferably is an aqueous solution. In certain embodiments, the bi-functional polypeptide in the liquid solution is at a concentration of about 25 mg/mL to about 250 mg/mL (e.g., 40 mg/mL, 50 mg/mL, 60 mg/mL, 75 mg/mL, 85 mg/mL, 100 mg/mL, 125 mg/mL, 150 mg/mL, 200 mg/mL). When the bi-functional polypeptide is provided as a lyophilized product, the bi-functional polypeptide is at about 75 mg/vial to about 200 mg/vial (e.g., 100 mg/vial, 108.5 mg/vial, 125 mg/vial, 150 mg/vial). The lyophilized powder is generally reconstituted by the addition of a suitable solvent. The solvent, e.g., sterile water or buffer (e.g., PBS), can optionally be provided in the kit.

The kit can include one or more containers for the composition or compositions containing the agents. In some embodiments, the kit contains separate containers, dividers or compartments for the composition and informational material. For example, the composition can be contained in a bottle, vial, or syringe, and the informational material can be contained in a plastic sleeve or packet. In other embodiments, the separate elements of the kit are contained within a single, undivided container. For example, the composition is contained in a bottle, vial or syringe that has attached thereto the informational material in the form of a label. In some embodiments, the kit includes a plurality (e.g., a pack) of individual containers, each containing one or more unit dosage forms (e.g., a dosage form described herein) of the agents. The containers can include a combination unit dosage, e.g., a unit that includes both the bi-functional polypeptide and the second agent, e.g., in a desired ratio. For example, the kit includes a plurality of syringes, ampules, foil packets, blister packs, or medical devices, e.g., each containing a single combination unit dose. The containers of the kits can be air tight, waterproof (e.g., impermeable to changes in moisture or evaporation), and/or light-tight.

The kit optionally includes a device suitable for administration of the composition, e.g., a syringe or other suitable delivery device. The device can be provided pre-loaded with one or both of the agents or can be empty, but suitable for loading.

EXAMPLES

The following examples are provided to better illustrate the claimed invention and are not to be interpreted as limiting the scope of the invention. To the extent that specific materials are mentioned, it is merely for purposes of illustration and is not intended to limit the invention. One skilled in the art can develop equivalent means or reactants without the exercise of inventive capacity and without departing from the scope of the invention.

Example 1: Bi-Functional Polypeptide

Exemplary single-chain bi-functional polypeptides comprising a first domain comprising an antigen binding domain of an antibody or functional fragment thereof which binds to an epitope of tau and a second domain comprising a proteasome-targeting PEST motif are provided below.

A bi-functional polypeptide comprises a first domain that is a single chain fragment (scFv) which binds to an epitope of tau, the scFv comprising a Tau specific V_(L) domain (V_(L) Tau) and a Tau specific V_(H) domain (V_(H) Tau).

The amino acid sequences for Tau specific V_(H) domain (V_(H) Tau) are provided in Table 2.

TABLE 2 Anti-tau scFV Heavy (V_(H)) domain sequences Sequence ID (CDR sequence regions identified in BOLD) A QVQLQESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEW VAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARDFAGAIAYWGQGTLVTVSS (SEQ ID NO: 1) B QVQLQQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEW VAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CAKDLVGAKGNWGQGTLVTVSS (SEQ ID NO: 2) C QVQLQESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEW VAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARDFAGAIAYWGQGTLVTVSS (SEQ ID NO: 3) D QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWV AAISGSGDNTYYADSVKGRFTISRDNSENTVHLQMAGLRAEDTALYFCA KDGPAVGNPQGYFDFWGRGTLVTVSS (SEQ ID NO: 4) E QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEW VASMSYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARDLRGALDYWGQGTLVTVSS (SEQ ID NO: 5) F QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEWVS SISSSSSYIYVADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARD GIAARSGYYGMDVWGQGTLVTVSS (SEQ ID NO: 6) G QVQLQESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEW VAVISYDGSNKYVADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARDFAGAIAYWGQGTLVTVSS (SEQ ID NO: 7) K QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWV AAISGSGDNTYVADSVKGRFTISRDNSENTVHLQMAGLRAEDTALYFCA KDGPAVGNPQGYFDFWGRGTLVTVSS (SEQ ID NO: 8) M QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEW VAVISYDGSNKYVADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CAKDLPDSNGYWGQGTLVTVSS (SEQ ID NO: 9) N QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWV AAISGSGDNTYVADSVKGRFTISRDNSENTVHLQMAGLRAEDTALYFCA KDGPAVGNPGGYFDFWGRGTLVTVSS (SEQ ID NO: 10) O QVQLVQSGGGVVHPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEW VASMSYDGNNKYVADSVKGRFTTPRDNSKNTLYLQMNSLRAEDTAVY YCARDLRGALDYWGQGTLVTVSS (SEQ ID NO: 11) Q QVQLQESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEW VAVISYDGSNKYVADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARDFAGAIAYWGQGTLVTVSS (SEQ ID NO: 12) S QVQLQQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWARQAPGKGLEW VAVISYDGSNKYVADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CAKDLVGAKGNWAQGTLVTVSS (SEQ ID NO: 13) T QVQLQQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEW VAVISYDGSNKYVADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CAKDLVGAKGNWGQGTLVTVSS (SEQ ID NO: 14) V QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWV AAISGSGDNTYVADSVKGRFTISRDNSENTVHLQMAGLRAEDTALYFCA KDGPEVGNPGGYFDFWGRGTLVTVSS (SEQ ID NO: 15) X QVQLQQSGEGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEWV AVISYDGSNKYVADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC AKDLVGAKGNWGQGTLVTVSS (SEQ ID NO: 16) Y QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLEW VASMSYDGDNKYVADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYY CARDLRGALDYWGQGTLVTVSS (SEQ ID NO: 17)

The amino acid sequences of Tau specific V_(L) domain (V_(L) Tau) are provided in Table 3.

TABLE 3 Anti-tau scFV Light (V_(L)) domain sequences scFV ID (CDR sequence regions identified in BOLD) A EIVLTQSPSFLSASVGDRVTITCRASHGINNYLAWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGG TK (SEQ ID NO: 18) B EIVLTQSPSTLSASVGERVTITCRASQSISSWLAWYQQKPGKAPKVLIYK ASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSTYLWTFGQ GTK (SEQ ID NO: 19) C EIVLTQSPSILSASVGDRVTITCRASHGINNYLAWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQ GTK (SEQ ID NO: 20) D DIVMTQSPDSLAVSLGERATINCKSSQSLLYSSNNKDYLAWYQQKPGQS PRLLISWASTRESGVPDRFSGSGSGTDFTLTINRLQAEDVAVYYCQHYYS YPLTFGQGTK (SEQ ID NO: 21) E EIVLTQSPSTLSASIGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYAA STLQSGVPSRFSGSGSGTEFTLTISGLLPEDFASYFCQQASVFPVTFGGGT K (SEQ ID NO: 22) F EIVLTQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYA ASILQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDSNPYPLLTFG GGTK (SEQ ID NO: 23) G EIVLTQSPSFLSASVGDRVTITCRASHGINNYLAWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFART K (SEQ ID NO: 24) K DIVMTQSPDSLAVSLGERATINCKSSQSLLYSSNNKDYLAWYQQKPGQS PRLLISWASTRESGVPSRFSGSGSGTDFTLTINRLQAEDVAVYYCQHYYS YPLTFGQGTK (SEQ ID NO: 25) M DVVMTQSPSTLSASVGDRVTITCRASENINRWLAWYQQKPGKAPKLLIY KASSLESGVPSRCSGSGSGTEFTLTISSLQPDDFATYYCHQYTTYLWTFG QGTK (SEQ ID NO: 26) N DIVMTQSPDSLAVSLGERATINCKSSQSLLYSSNNKDYLAWYQQKPGQS PRLLIPWASTRESGVPDRFSGSGSGTDFTLTINRLQAEDVAVYYCQHYYS YPLTFGQGTK (SEQ ID NO: 27) O EIVLTQSPSTLSASIGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYAA STLQSGVPSRFSGSGSGTEFTLTISGLLPEDFASYFCQQASVFPVTFARTK (SEQ ID NO: 28) Q EICVTQSPSFLSASVGDRVTITCRASHGINNYLAWYQQKPGKAPKLLIYA ASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGG TK (SEQ ID NO: 29) S EIVLTQSPSTLSASVGERVTITCRASQSISSWLAWYQQKPGKAPKVLIYK ASSLESGVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSTYLWTFGQ GTK (SEQ ID NO: 30) T EIVLTQSPSTLSASVGERVTITCRASQSISSWLAWYQQKPGKAPKVLIYK ASSLESGVPDRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSTYLWTFGQ GTK (SEQ ID NO: 31) V DIVMTKSPDSLAVSLGERATINCKSSQSLLYSSKNKDYLAWYQKKPGQS PRLLISWASTRESGVPDRFSGSGSGTDFTLTINRLQAEDVAVYYCQHYYS YPLTFGQGTK (SEQ ID NO: 32) X EIVLTQSPSTLSASVGERVTITCRASQSISSWLAWYQQKPGKAPKVLIYK ASSLESGVPSFRSGSGSGTEFTLTISSLQPDDFATYYCQQYSTYLWTFGQ GTK (SEQ ID NO: 33) Y EIVLTQSPSTLSASIGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYAA STLQSGVPSRFSGSGSGTEFTLTISGLLPEDFASYFCLQASVFPVTFGGGT K (SEQ ID NO: 34)

The Tau specific V_(L) domain (V_(L) Tau) and a Tau specific V_(H) domain (V_(H) Tau) may be directly connected or linked via a polypeptide linker. For example, the Tau specific V_(L) domain (V_(L) Tau) and a Tau specific V_(H) domain (V_(H) Tau) are connected via a polypeptide linker that has an amino acid sequence that is at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or 100% identical to an amino acid set forth in SEQ ID NO: 35 (GGGGSGGGGSGGGGS) or SEQ ID NO: 37 (YPYDVPDYA).

Amino Acid Sequence of HA Epitope:

(SEQ ID NO: 37) YPYDVPDYA.

The amino acid sequences for bi-functional polypeptides comprising an anti-Tau binding domain and a murine derived PEST domain are provided in Table 4.

TABLE 4 Anti-tau_mPEST bi-functional polypeptide amino acid sequences Intrabody (HA epitope sequence region identified in BOLD; murine PEST ID sequence region identified in UNDERLINE) A_Anti- QVQLQESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLE Tau-mPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCARDFAGAIAYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSP SFLSASVGDRVTITCRASHGINNYLAWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKYP YDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV (SEQ ID NO: 40) B Anti- QVQLQQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-mPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCAKDLVGAKGNWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQS PSTLSASVGERVTITCRASQSISSWLAWYQQKPGKAPKVLIYKASSLES GVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSTYLWTFGQGTKYP YDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV (SEQ ID NO: 41) C Anti- QVQLQESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLE Tau-mPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCARDFAGAIAYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSP SILSASVGDRVTITCRASHGINNYLAWYQQKPGKAPKLLIYAASSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKYPY DVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV (SEQ ID NO: 42) D Anti- QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEW Tau-mPEST VAAISGSGDNTYYADSVKGRFTISRDNSENTVHLQMAGLRAEDTALY FCAKDGPAVGNPQGYFDFWGRGTLVTVSSGGGGSGGGGSGGGGSDIV MTQSPDSLAVSLGERATINCKSSQSLLYSSNNKDYLAWYQQKPGQSPR LLISWASTRESGVPDRFSGSGSGTDFTLTINRLQAEDVAVYYCQHYYS YPLTFGQGTKYPYDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDR HPAACASARINV (SEQ ID NO: 43) E Anti- QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-mPEST WVASMSYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTA VYYCARDLRGALDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQ SPSTLSASIGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYAASTLQ SGVPSRFSGSGSGTEFTLTISGLLPEDFASYFCQQASVFPVTFGGGTKYP YDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV (SEQ ID NO: 44) F Anti- QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEW Tau-mPEST VSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC ARDGIAARSGYYGMDVWGQGTLVTVSSGGGGSGGGGSGGGGSEIVL TQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYAASI LQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDSNPYPLLTFGGG TKYPYDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASA RINV (SEQ ID NO: 45) G Anti- QVQLQESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLE Tau-mPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCARDFAGAIAYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSP SFLSASVGDRVTITCRASHGINNYLAWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFARTKYPY DVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV (SEQ ID NO: 46) K Anti- QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEW Tau-mPEST VAAISGSGDNTYYADSVKGRFTISRDNSENTVHLQMAGLRAEDTALY FCAKDGPAVGNPQGYFDFWGRGTLVTVSSGGGGSGGGGSGGGGSDIV MTQSPDSLAVSLGERATINCKSSQSLLYSSNNKDYLAWYQQKPGQSPR LLISWASTRESGVPSRFSGSGSGTDFTLTINRLQAEDVAVYYCQHYYSY PLTFGQGTKYPYDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRH PAACASARINV (SEQ ID NO: 47) M Anti- QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-mPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCAKDLPDSNGYWGQGTLVTVSSGGGGSGGGGSGGGGSDVVMTQS PSTLSASVGDRVTITCRASENINRWLAWYQQKPGKAPKLLIYKASSLES GVPSRCSGSGSGTEFTLTISSLQPDDFATYYCHQYTTYLWTFGQGTKY PYDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARIN V (SEQ ID NO: 48) N Anti- QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEW Tau-mPEST VAAISGSGDNTYYADSVKGRFTISRDNSENTVHLQMAGLRAEDTALY FCAKDGPAVGNPGGYFDFWGRGTLVTVSSGGGGSGGGGSGGGGSDIV MTQSPDSLAVSLGERATINCKSSQSLLYSSNNKDYLAWYQQKPGQSPR LLIPWASTRESGVPDRFSGSGSGTDFTLTINRLQAEDVAVYYCQHYYS YPLTFGQGTKYPYDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDR HPAACASARINV (SEQ ID NO: 49) O Anti- QVQLVQSGGGVVHPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-mPEST WVASMSYDGNNKYYADSVKGRFTTPRDNSKNTLYLQMNSLRAEDTA VYYCARDLRGALDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQ SPSTLSASIGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYAASTLQ SGVPSRFSGSGSGTEFTLTISGLLPEDFASYFCQQASVFPVTFARTKYPY DVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV (SEQ ID NO: 50) Q Anti- QVQLQESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLE Tau-mPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCARDFAGAIAYWGQGTLVTVSSGGGGSGGGGSGGGGSEICVTQSP SFLSASVGDRVTITCRASHGINNYLAWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKYP YDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV (SEQ ID NO: 51) S Anti- QVQLQQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWARQAPGKGLE Tau-mPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCAKDLVGAKGNWAQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQS PSTLSASVGERVTITCRASQSISSWLAWYQQKPGKAPKVLIYKASSLES GVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSTYLWTFGQGTKYP YDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV (SEQ ID NO: 52) T Anti- QVQLQQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-mPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCAKDLVGAKGNWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQS PSTLSASVGERVTITCRASQSISSWLAWYQQKPGKAPKVLIYKASSLES GVPDRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSTYLWTFGQGTKY PYDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARIN V (SEQ ID NO: 53) V Anti- QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEW Tau-mPEST VAAISGSGDNTYYADSVKGRFTISRDNSENTVHLQMAGLRAEDTALY FCAKDGPEVGNPGGYFDFWG7RGTLVTVSSGGGGSGGGGSGGGGSDI VMTKSPDSLAVSLGERATINCKSSQSLLYSSKNKDYLAWYQKKPGQSP RLLISWASTRESGVPDRFSGSGSGTDFTLTINRLQAEDVAVYYCQHYY SYPLTFGQGTKYPYDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMD RHPAACASARINV (SEQ ID NO: 54) X Anti- QVQLQQSGEGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-mPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCAKDLVGAKGNWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQS PSTLSASVGERVTITCRASQSISSWLAWYQQKPGKAPKVLIYKASSLES GVPSFRSGSGSGTEFTLTISSLQPDDFATYYCQQYSTYLWTFGQGTKYP YDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV (SEQ ID NO: 55) Y Anti- QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-mPEST WVASMSYDGDNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTA VYYCARDLRGALDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQ SPSTLSASIGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYAASTLQ SGVPSRFSGSGSGTEFTLTISGLLPEDFASYFCLQASVFPVTFGGGTKYP YDVPDYASHGFPPEVEEQDDGTLPMSCAQESGMDRHPAACASARINV (SEQ ID NO: 56)

The amino acid sequences for exemplary bi-functional polypeptides comprising an anti-Tau binding domain and a murine derived PEST domain are provided in Table 5.

TABLE 5 Anti-tau_hPEST bi-functional polypeptide amino acid sequences Intrabody (HA epitope sequence region identified in BOLD; murine PEST ID sequence region identified in UNDERLINE) A_Anti- QVQLQESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLE Tau-hPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCARDFAGAIAYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSP SFLSASVGDRVTITCRASHGINNYLAWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKYP YDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV (SEQ ID NO: 57) B Anti- QVQLQQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-hPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCAKDLVGAKGNWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQS PSTLSASVGERVTITCRASQSISSWLAWYQQKPGKAPKVLIYKASSLES GVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSTYLWTFGQGTKYP YDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV (SEQ ID NO: 58) C Anti- QVQLQESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLE Tau-hPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCARDFAGAIAYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSP SILSASVGDRVTITCRASHGINNYLAWYQQKPGKAPKLLIYAASSLQSG VPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPWTFGQGTKYPY DVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV (SEQ ID NO: 59) D Anti- QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEW Tau-hPEST VAAISGSGDNTYYADSVKGRFTISRDNSENTVHLQMAGLRAEDTALY FCAKDGPAVGNPQGYFDFWGRGTLVTVSSGGGGSGGGGSGGGGSDIV MTQSPDSLAVSLGERATINCKSSQSLLYSSNNKDYLAWYQQKPGQSPR LLISWASTRESGVPDRFSGSGSGTDFTLTINRLQAEDVAVYYCQHYYS YPLTFGQGTKYPYDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKR HRAACASASINV (SEQ ID NO: 60) E Anti- QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-hPEST WVASMSYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTA VYYCARDLRGALDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQ SPSTLSASIGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYAASTLQ SGVPSRFSGSGSGTEFTLTISGLLPEDFASYFCQQASVFPVTFGGGTKYP YDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV (SEQ ID NO: 61) F Anti- QVQLVESGGGLVKPGGSLRLSCAASGFTFSDYYMSWIRQAPGKGLEW Tau-hPEST VSSISSSSSYIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYC ARDGIAARSGYYGMDVWGQGTLVTVSSGGGGSGGGGSGGGGSEIVL TQSPSTLSASVGDRVTITCRASQSISSWLAWYQQKPGKAPKLLIYAASI LQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCLQDSNPYPLLTFGGG TKYPYDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASA SINV (SEQ ID NO: 62) G Anti- QVQLQESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLE Tau-hPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCARDFAGAIAYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQSP SFLSASVGDRVTITCRASHGINNYLAWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFARTKYPY DVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV (SEQ ID NO: 63) K Anti- QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEW Tau-hPEST VAAISGSGDNTYYADSVKGRFTISRDNSENTVHLQMAGLRAEDTALY FCAKDGPAVGNPQGYFDFWGRGTLVTVSSGGGGSGGGGSGGGGSDIV MTQSPDSLAVSLGERATINCKSSQSLLYSSNNKDYLAWYQQKPGQSPR LLISWASTRESGVPSRFSGSGSGTDFTLTINRLQAEDVAVYYCQHYYSY PLTFGQGTKYPYDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRH RAACASASINV (SEQ ID NO: 64) M Anti- QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-hPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCAKDLPDSNGYWGQGTLVTVSSGGGGSGGGGSGGGGSDVVMTQS PSTLSASVGDRVTITCRASENINRWLAWYQQKPGKAPKLLIYKASSLES GVPSRCSGSGSGTEFTLTISSLQPDDFATYYCHQYTTYLWTFGQGTKY PYDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASIN V (SEQ ID NO: 65) N Anti- QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEW Tau-hPEST VAAISGSGDNTYYADSVKGRFTISRDNSENTVHLQMAGLRAEDTALY FCAKDGPAVGNPGGYFDFWGRGTLVTVSSGGGGSGGGGSGGGGSDIV MTQSPDSLAVSLGERATINCKSSQSLLYSSNNKDYLAWYQQKPGQSPR LLIPWASTRESGVPDRFSGSGSGTDFTLTINRLQAEDVAVYYCQHYYS YPLTFGQGTKYPYDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKR HRAACASASINV (SEQ ID NO: 66) O Anti- QVQLVQSGGGVVHPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-hPEST WVASMSYDGNNKYYADSVKGRFTTPRDNSKNTLYLQMNSLRAEDTA VYYCARDLRGALDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQ SPSTLSASIGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYAASTLQ SGVPSRFSGSGSGTEFTLTISGLLPEDFASYFCQQASVFPVTFARTKYPY DVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV (SEQ ID NO: 67) Q Anti- QVQLQESGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLE Tau-hPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCARDFAGAIAYWGQGTLVTVSSGGGGSGGGGSGGGGSEICVTQSP SFLSASVGDRVTITCRASHGINNYLAWYQQKPGKAPKLLIYAASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQANSFPLTFGGGTKYP YDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV (SEQ ID NO: 68) S Anti- QVQLQQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWARQAPGKGLE Tau-hPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCAKDLVGAKGNWAQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQS PSTLSASVGERVTITCRASQSISSWLAWYQQKPGKAPKVLIYKASSLES GVPSRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSTYLWTFGQGTKYP YDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV (SEQ ID NO: 69) T Anti- QVQLQQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-hPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCAKDLVGAKGNWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQS PSTLSASVGERVTITCRASQSISSWLAWYQQKPGKAPKVLIYKASSLES GVPDRFSGSGSGTEFTLTISSLQPDDFATYYCQQYSTYLWTFGQGTKY PYDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASIN V (SEQ ID NO: 70) V Anti- QVQLVESGGGLVKPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEW Tau-hPEST VAAISGSGDNTYYADSVKGRFTISRDNSENTVHLQMAGLRAEDTALY FCAKDGPEVGNPGGYFDFWGRGTLVTVSSGGGGSGGGGSGGGGSDIV MTKSPDSLAVSLGERATINCKSSQSLLYSSKNKDYLAWYQKKPGQSPR LLISWASTRESGVPDRFSGSGSGTDFTLTINRLQAEDVAVYYCQHYYS YPLTFGQGTKYPYDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKR HRAACASASINV (SEQ ID NO: 71) X Anti- QVQLQQSGEGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-hPEST WVAVISYDGSNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAV YYCAKDLVGAKGNWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQS PSTLSASVGERVTITCRASQSISSWLAWYQQKPGKAPKVLIYKASSLES GVPSFRSGSGSGTEFTLTISSLQPDDFATYYCQQYSTYLWTFGQGTKYP YDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV (SEQ ID NO: 72) Y Anti- QVQLVQSGGGVVQPGRSLRLSCAASGFTFSSYGMHWVRQAPGKGLE Tau-hPEST WVASMSYDGDNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTA VYYCARDLRGALDYWGQGTLVTVSSGGGGSGGGGSGGGGSEIVLTQ SPSTLSASIGDRVTITCRASQGISNYLAWYQQKPGKAPKLLIYAASTLQ SGVPSRFSGSGSGTEFTLTISGLLPEDFASYFCLQASVFPVTFGGGTKYP YDVPDYANPDFPPEVEEQDASTLPVSCAWESGMKRHRAACASASINV (SEQ ID NO: 73)

Example 2

Anti-Tau-mousePEST (mPEST) intrabodies were screened in the ST14A cell line that was previously described in detail (Ehrlich, M. E., et. al., ST14A Cells Have Properties of a Medium-Size Spiny Neuron, Experimental Neurology, Volume 167, Issue 2, 2001, Pages 215-226) Cells were propagated at the permissive temperature of 33° C. in Dulbecco's modified Eagle medium (Life Technologies, Bethesda, Md.) supplemented with 0.11 g/liter sodium pyruvate, 3.7 g/liter sodium bicarbonate, 0.29 g/liter glutamine, 3.9 g/liter Hepes, 100 units/ml penicillin—streptomycin (Life Technologies), plus 10% fetal calf serum. Anti-tau-mPEST intrabodies were subcloned into pcDNA3.1- and co-transfected with pTetO-FUW-GFP-Tau (2N4R) and rtTA. A flexible (G45)4 linker was placed between GFP and Tau to allow independent folding of the two proteins. 4 hours after transfection, PEI transfection reagent was aspirated off of cells, and media was replaced with ST14A media supplemented with 2000 ng/mL doxycycline to induce maximal GFP-Tau expression. 48H after transfection, cells were imaged for GFP-tau fluorescence at 32× magnification (FIG. 3) and at 50 magnification (FIG. 4) An n of 2 was performed for each intrabody. Reductions in GFP mean fluorescence intensity correspond to reductions of the fused protein.

Live cell imaging of transfected cells revealed that without anti-Tau intrabodies (see CON+GFP-Tau; empty pcDNA3.1 plasmid), GFP remained diffuse throughout the cells. In cells co-transfected with anti-Tau-mPEST intrabodies resulted in a dramatic reduction of observable GFP fluorescence. See, for example, FIG. 3 and FIG. 4 which demonstrate a dramatic reduction of observable GFP fluorescence in cells co-transfected with anti-Tau-mPEST intrabodies E-mPEST+GFP-Tau, N-mPEST+GFP-Tau, O-mPEST+GFP-Tau, T-mPEST+GFP-Tau, V-mPEST+GFP-Tau, and X-mPEST+GFP-Tau.

OTHER EMBODIMENTS

It is to be understood that while the invention has been described in conjunction with the detailed description thereof, the foregoing description is intended to illustrate and not limit the scope of the invention, which is defined by the scope of the appended claims. Other aspects, advantages, and modifications are within the scope of the following claims. 

1.-46. (canceled)
 47. An anti-tau bi-functional polypeptide, comprising a polypeptide having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NO: 45, SEQ ID NO: 54, SEQ ID NO: 49, SEQ ID NO: 40, SEQ ID NO: 44, SEQ ID NO: 48, SEQ ID NO: 55, SEQ ID NO: 53, SEQ ID NO: 50, and SEQ ID NO: 52, wherein percent identity is determined using the BLASTP algorithm.
 48. An anti-tau bi-functional polypeptide, comprising a polypeptide having an amino acid sequence at least 90% identical to a sequence selected from the group consisting of SEQ ID NO: 62, SEQ ID NO: 71, SEQ ID NO: 66, SEQ ID NO: 57, SEQ ID NO: 61, SEQ ID NO: 65, SEQ ID NO: 72, SEQ ID NO: 70, SEQ ID NO: 67, and SEQ ID NO: 69, wherein percent identity is determined using the BLASTP algorithm.
 49. A bi-functional polypeptide, comprising (a) a first domain of an intrabody which binds to an epitope of Tau wherein the intrabody is an antibody fragment (scFv) including a Tau specific V_(L) immunoglobulin domain (V_(L) Tau) and a Tau specific V_(H) immunoglobulin domain (V_(H) Tau) connected by a first linker, wherein the first linker is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO: 35; wherein the V_(H) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 6; and wherein the V_(L) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 23; (ii) the V_(H) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 15; and wherein the V_(L) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 32; (iii) the V_(H) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 10; and wherein the V_(L) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 27; (iv) the V_(H) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 1; and wherein the V_(L) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 18; (v) the V_(H) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 5; and wherein the V_(L) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 22; (vi) the V_(H) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 9; and wherein the V_(L) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 26; (vii) the V_(H) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 16; and wherein the V_(L) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 33; (viii) the V_(H) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 14; and wherein the V_(L) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 31; (ix) the V_(H) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 11; and wherein the V_(L) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 28; or (x) the V_(H) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 13; and wherein the V_(L) Tau domain is at least 90% identical to an amino acid sequence as set forth in SEQ ID NO: 30; and (b) a second domain comprising a proteasome-targeting PEST motif having an amino acid sequence at least 90% identical to the amino acid sequence as set forth in SEQ ID NO: 38 or SEQ ID NO: 39; wherein percent identity is determined using the BLASTP algorithm.
 50. The polypeptide of claim 49, wherein the second domain is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:
 38. 51. The polypeptide of claim 49, wherein the second domain is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:
 39. 52. The polypeptide of claim 49, wherein the first domain and the second domain are connected by a second linker.
 53. The polypeptide of claim 52, wherein the second linker is at least 90% identical to the amino acid sequence as set forth in SEQ ID NO:
 37. 54. The polypeptide of claim 49, wherein the domains are arranged in the order of V_(L)Tau-linker-V_(H)Tau-PEST motif.
 55. The polypeptide of claim 49, wherein the domains are arranged in the order of V_(H)Tau-linker-V_(L)Tau-PEST motif.
 56. A polynucleotide encoding the bi-functional polypeptide of claim
 49. 57. A vector comprising a polynucleotide encoding the bifunctional polypeptide of claim
 56. 58. An isolated host cell transfected with the polynucleotide of claim
 56. 59. An isolated host cell transfected with the vector of claim
 57. 60. A method for the preparation of a bi-functional polypeptide comprising: cultivating a host cell transfected with a polynucleotide which upon expression encodes the bi-functional polypeptide of claim 49; and isolating the polypeptide from the cell.
 61. A composition comprising the bi-functional polypeptide of claim
 49. 62. The composition of claim 61, further comprising a pharmaceutically acceptable carrier.
 63. A method for the treatment a tauopathy in a patient, which comprises administering to the patient in need of such treatment a therapeutically effective amount of the bi-functional polypeptide of claim
 49. 64. The method of claim 63, wherein the tauopathy is selected from the group consisting of Alzheimer's Disease (AD), progressive supranuclear palsy (PSP), frontotemporal dementia with Parkinsonism on chromosome-17 (FTDP-17), corticobasal degeneration (CBD), Pick's disease, chronic traumatic encephalopathy (CTE), Lewy Body dementia, tuberous sclerosis, traumatic brain injury (TBI), Down syndrome, Guam parkinsonism dementia complex, Dementia pugilistica, Dementia with argyrophilic grains, Pallido-ponto-nigral degeneration, and Gerstmann-Straussler-Scheinker disease. 